Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.
People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...
Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...
Please provide your email address to receive an email when new articles are posted on . The strongest treatment effect for fenebrutinib was observed from baseline in the 9-Hole Peg Test. Safety ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid ...
SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
Multiple sclerosis (MS) is an inflammatory condition that damages the myelin of the central nervous system, leading to neurologic impairment and possibly severe disability. MS is characterized by ...
Process mining and representation learning applied to 447,222 patients revealed nuanced pre-diagnostic pathways associated with delayed MS diagnosis, implicating referral friction, misdiagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results